Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TELESTO deferasirox versus placebo in low/int-1 risk MDS with transfusional iron overload
NL-OMON38011Phase 3Withdrawn
- Sponsor
- Novartis
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in iron overload and myelodysplastic syndrome (MDS) comparing Exjade with Placebo (2 arms). Primary endpoint: Event-free survival. Planned start Feb 2011; status: withdrawn.
02
Drugs
deferasirox
03
Conditions
iron overloadmyelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON38011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38011.